HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

C&D Strategy Aims To Strengthen Toothpastes, Deodorants

This article was originally published in The Rose Sheet

Executive Summary

Church & Dwight has established new guerrilla marketing and cross-functional teams tasked with slowing declines of the company's underarm deodorant and value toothpaste brands, the firm announced during a first-quarter May 8 analyst call

You may also be interested in...



Sales & Earnings In Brief

Procter & Gamble: Double-digit growth of P&G's prestige fragrances business was central to fourth-quarter and fiscal 2007 growth, according to an Aug. 3 release. Full-year net beauty sales increased 9% to $23.0 billion, firm says, attributing growth to Boss Selection and Boss Femme fragrance initiatives and the addition of Dolce & Gabbana's The One through a July 2006 licensing deal (1"The Rose Sheet" Dec. 19, 2005, In Brief). High single-digit skin-care growth was driven by Olay Definity and Regenerist, while hair-care sales increased by mid-single-digits on strong performances from Pantene, Head & Shoulders and Herbal Essences, P&G says. Q4 beauty sales totaled $5.9 bil., up 8%, with significant contributions coming from Escada and Lacoste within firm's prestige fragrances segment, as well as Dolce & Gabbana. Overall, company sales for the year rose 12% to $76.5 bil. Fourth-quarter revenue was up 8% to $19.3 bil. Double-digit increases in Blades & Razors and Health Care divisions were driven by sales of Gillette Fusion and Crest Pro-Health; Fiscal 2008 sales are expected to grow 5% to 7%...

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014704

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel